Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Cash from Financing Activities (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Cash from Financing Activities for 6 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 99.24% to $2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.9 million, a 99.31% decrease, with the full-year FY2025 number at $4.9 million, down 99.31% from a year prior.
  • Cash from Financing Activities was $2.9 million for Q4 2025 at Janux Therapeutics, up from $493000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $386.6 million in Q4 2024 to a low of -$843000.0 in Q3 2021.
  • A 5-year average of $61.3 million and a median of $954000.0 in 2025 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: tumbled 2454.55% in 2021, then soared 157900.0% in 2023.
  • Janux Therapeutics' Cash from Financing Activities stood at $164000.0 in 2021, then rose by 16.46% to $191000.0 in 2022, then soared by 335.08% to $831000.0 in 2023, then surged by 46428.28% to $386.6 million in 2024, then crashed by 99.24% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Cash from Financing Activities are $2.9 million (Q4 2025), $493000.0 (Q3 2025), and $954000.0 (Q2 2025).